Loading...
•
Dec 31, 2021
Anika Q4 2021 Earnings Report
Anika reported fourth quarter and year-end results, showing revenue growth despite COVID headwinds and progress in operational transformation.
Key Takeaways
Anika Therapeutics reported a 10% year-over-year revenue growth in the fourth quarter, ending the year with a 13% revenue increase for fiscal year 2021. The company faced COVID-related market challenges but saw strong growth in its Joint Preservation and Restoration business.
Fourth quarter revenue grew by 10% year-over-year despite COVID headwinds.
Full-year 2021 revenue increased by 13%, driven by strong growth in Joint Preservation and Restoration.
The Joint Preservation and Restoration business delivered 23% revenue growth for the year.
Anika made significant progress on its operational transformation, establishing a foundation for multi-year growth strategy.
Forward Guidance
Anika expects overall revenue for fiscal year 2022 to be up low to mid-single digit percent compared with 2021, due to the ongoing global COVID-related environment and its expected impact on elective procedures.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...